External broker reports(aggregated public sources), Sharekhan

Sharekhan

External broker reports(aggregated public sources)

Sharekhan is India's leading broking house providing services from easy online trading, research to wide array of financial products. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Dabur India Ltd. manufactures soaps, detergents, hair oils, tooth powders, antacids and processed foods. The Company sells its products worldwide.

<ul><li>Dabur India (Dabur) to post mid to high single-digit revenue growth in Q1FY2025 with domestic volume growth of mid-single digits.</li><li>Gross margins and OPM to remain high y-o-y; operating profit to grow marginally ahead of revenue growth.</li><li>We expect Revenue/PAT to grow by 6%/7% y-o-y respectively in Q1. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dabur India (Dabur) to post mid to high single-digit revenue growth in Q1FY2025 with domestic volume growth of mid-single digits.Gross margins and OPM to remain high y-o-y; operating profit to grow marginally ahead of revenue growth.We expect Revenue/PAT to grow by 6%/7% y-o-y respectively in Q1. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dabur India Ltd - Good Q1 Update; Volume Growth Trend to Improve

Asian Paints Limited manufactures a wide range of decorative paints, varnishes, enamels, and black & synthetic resins. The Company, through its subsidiaries, also manufactures specialty industrial chemicals and vinyl pyridine latex products which are used in the manufacture of rubber tires.

<ul><li>Prudent capacity expansion plan, sustained innovation, backward integration and improving customer experience will help APL navigate through the tough times of heightened competition in the near term.</li><li>OPM to remain flat over the next two years.</li><li>Contribution from new launches came in at 11% in FY2024 (it added 24/16 products in decorative/industrial paints in FY2024).</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Prudent capacity expansion plan, sustained innovation, backward integration and improving customer experience will help APL navigate through the tough times of heightened competition in the near term.OPM to remain flat over the next two years.Contribution from new launches came in at 11% in FY2024 (it added 24/16 products in decorative/industrial paints in FY2024).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Asian Paints Ltd - Upgrade to Buy; Risk Reward Favourable

Federal Bank Limited operates branches and regional offices throughout India. The Bank offers a wide range of financial services, including merchant banking, international banking and foreign exchange, leasing facilities, money markets and agricultural advances. The Bank also provides lending for hi-tech agricultural and government sponsored schemes.

<ul><li>Federal Bank Federal Bank sustained a strong loan growth of 20% y-o-y/5% q-o-q in Q1FY25, despite seasonally a weak quarter and expectation of marginally slowdown in business momentum.</li><li>Retail advances grew by 25% y-o-y, while wholesale loans grew by 14% y-o-y segment.</li><li>CASA growth picked up (+5% q-o-q vs 1% in last quarter) while the bank sustained healthy retail term deposits growth (+5% q-o-q) which resulted in healthy deposits growth of 20% YoY/5% q-o-q.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Federal Bank Federal Bank sustained a strong loan growth of 20% y-o-y/5% q-o-q in Q1FY25, despite seasonally a weak quarter and expectation of marginally slowdown in business momentum.Retail advances grew by 25% y-o-y, while wholesale loans grew by 14% y-o-y segment.CASA growth picked up (+5% q-o-q vs 1% in last quarter) while the bank sustained healthy retail term deposits growth (+5% q-o-q) which resulted in healthy deposits growth of 20% YoY/5% q-o-q.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Federal Bank - FY25 Begins on a Strong Note

Standard Industries Limited manufactures chemicals and textile goods. The Company's products include caustic soda, caustic potash, hydrochloric acid, potassium carbonate, ethyl chloride and hydrogen gas.  Standard Industries' textile products include grey long cloths, poplins, printed textiles, drills, crepes and voiles which are sold under the COCKATOO and SAPERA trade names.

<ul><li>Sharekhan's research report onSupreme Industries Growth momentum continued in April-May as overall volumes rose 22% y-o-y, while plastic pipe volumes rose 27% y-o-y.</li><li>Sales including other income were up 12% y-o-y.</li><li>Management retained overall volume growth guidance of 20% y-o-y and plastic pipe system guidance of 25% y-o-y for FY2025. Average PVC prices rose ~9% in April-May 2024 as compared to Q4FY2024 average.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sharekhan's research report onSupreme Industries Growth momentum continued in April-May as overall volumes rose 22% y-o-y, while plastic pipe volumes rose 27% y-o-y.Sales including other income were up 12% y-o-y.Management retained overall volume growth guidance of 20% y-o-y and plastic pipe system guidance of 25% y-o-y for FY2025. Average PVC prices rose ~9% in April-May 2024 as compared to Q4FY2024 average.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Supreme Industries Ltd - Strong Headstart for FY2025

Biocon Ltd., is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immunosuppressants and anti-diabetic drugs. Biocon also manufactures specialty enzymes and new enzyme applications besides providing clinical and custom research services.

<ul><li>Biocon recently signed an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for commercialisation of its vertically integrated, complex drug product, Synthetic Liraglutide.</li><li>Liraglutide is an injection in pre-filled pen, used to treat chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity.</li><li>Biocon will undertake the development, manufacturing, and supply of the drug product, and Handok will be responsible for obtaining regulatory approvals and commercialization in the South Korean market.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon recently signed an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for commercialisation of its vertically integrated, complex drug product, Synthetic Liraglutide.Liraglutide is an injection in pre-filled pen, used to treat chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity.Biocon will undertake the development, manufacturing, and supply of the drug product, and Handok will be responsible for obtaining regulatory approvals and commercialization in the South Korean market.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon Ltd - GLP Product Launch a Big Opportunity